Novavax
NVAX
About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Employees: 1,992
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
62% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 50
21% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 43
2% more funds holding
Funds holding: 241 [Q1] → 247 (+6) [Q2]
2% more capital invested
Capital invested by funds: $631M [Q1] → $643M (+$11.2M) [Q2]
0.83% more ownership
Funds ownership: 61.23% [Q1] → 62.06% (+0.83%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
31% less call options, than puts
Call options by funds: $52.9M | Put options by funds: $76.6M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Sean Lee
|
$10
|
Buy
Assumed
|
28 Aug 2025 |
|
B of A Securities
Alec Stranahan
|
$7
|
Underperform
Downgraded
|
20 Aug 2025 |
|
Citigroup
Geoff Meacham
|
$6
|
Sell
Initiated
|
17 Jun 2025 |
Financial journalist opinion
Based on 10 articles about NVAX published over the past 30 days
